🔬 Latest pharma industry updates 👇

🟢 GSK won FDA approval for Jideytro in advanced lung cancer, marking its 1st lung cancer approval, a significant cancer-treatment advance.

🤖 Insilico Medicine says its AI-driven platform now reaches drug candidates in 13 months versus 4.5 years traditionally.

🧬 Tempus AI will acquire cancer test maker Personalis, Inc. for $1.5B, expanding its position in blood-based cancer diagnostics amid growing medtech interest.

🚨 Ebola deaths passed 1,000, with 2,473 confirmed cases in Congo and warnings that underfunded response systems, distrust, shortages and overwhelmed hospitals could make it an international threat.

🏭 Samsung Biologics will acquire PolyPeptide Group for €1.58B, entering peptide therapeutics manufacturing.

🤖 Bristol Myers Squibb acquired NVIDIA’s DGX SuperPOD to expand AI-powered drug discovery, enabling broader early candidate screening and reportedly cutting clinical-trial drug manufacturing timelines by 20–30%.

💊 Latigo Biotherapeutics, Inc. and Scribe Therapeutics filed for IPOs to advance non-opioid pain drugs and gene editing and precision therapeutics.

⚠️ Trump announced generic drug tariffs starting in 2028, rising from 100% to 200%, aiming to force U.S. reshoring but risking higher costs for widely used low-margin medicines.

💊 Gilead Sciences and Merck’s weekly HIV pill combining lenacapavir and islatravir proved non-inferior to daily regimens.

⚖️ Novo Nordisk sued Eli Lilly and Company over allegedly misleading obesity drug advertising, claiming Lilly’s GLP-1 superiority messaging is deceptive, while Lilly says its campaign is truthful.

🧪 Dassault Systèmes will acquire clinical trial software provider ArisGlobal for $2B, reinforcing its life sciences strategy despite pressure from AI disruption concerns.

🧫 Repligen Corporation will buy BioLife Solutions, Inc. for $1.5B, adding cell preservation and processing tools widely used in commercial cell therapies.

📈 Arrowhead Pharmaceuticals’s plozasiran met Phase 3 goals in severe hypertriglyceridemia, cutting triglycerides by roughly 80% and reducing acute pancreatitis risk by 78%.

💉 U.S. measles cases reached 2,260 by mid-July, putting elimination status at risk as vaccination rates fall and outbreaks spread through under-vaccinated communities.

🏢 BeOne Medicines will invest $300M to expand its New Jersey R&D and manufacturing campus, supporting more than 35 oncology assets across clinical and commercial stages.

🏛️ Biotech leaders welcomed FDA rehiring plans after 3,000+ departures, stressing that restored scientific expertise and regulatory predictability are essential to sustain innovation.

⚖️ Eli Lilly and Company’s retatrutide met Phase 3 goals in obesity and diabetes trials, delivering substantial weight loss and improved glycemic control across high-risk patient groups.